DiaMedica Therapeutics (DMAC)

• Market cap: $274M
• 1 day: 31.62%
• 5 days: 18.48%
• 1 month: 59.45%
• 3 months: 55.21%
• 6 months: 181.14%
• Year to date: 126.50%
• 1 year: 140.98%
• 5 years: 58.27%
• 10 years: 106.77%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Employees: 19

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2,757% more call options, than puts

Call options by funds: $200K | Put options by funds: $7K

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

54% more capital invested

Capital invested by funds: $15.2M [Q2] → $23.3M (+$8.14M) [Q3]

25% more funds holding

Funds holding: 32 [Q2] → 40 (+8) [Q3]

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.51% less ownership

Funds ownership: 13.57% [Q2] → 13.05% (-0.51%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 9% upside
• Avg. target: $7 9% upside
• High target: $7 9% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target

9% upside $7

Buy Reiterated

15 Nov 2024